Table 1.
General characteristic of the included studies. 1, need for transfusion; 2, total blood loss; 3, hidden blood loss; 4, intraoperative blood loss; 5, the occurrence of DVT; 6, the occurrence of hematoma
| Author | Country | Age (years, I/C) | No. of patients (n) | Interventions | Dose of intervention | Outcomes | Transfusion threshold | Follow-up |
|---|---|---|---|---|---|---|---|---|
| Gao F 2015 | China | 58.6 vs 61.7 | 53 vs 54 | Topical TXA + topical DEP vs topical TXA | TXA (3 g), DEP (0.25 mg, 1:200000) | 1, 2, 3, 4, 5, 6 | Hb < 70 g/l | 3 months |
| Jans O 2016 | Denmark | 67 vs 69 | 50 vs 50 | Intravenous TXA + intravenous DEP vs intravenous TXA | TXA (1 g), DEP (0.05 μg kg−1 min−1) | 2,3, | Hb < 80 g/l | At discharge |
| Liu JL 2018 | China | 50.0 vs 50.2 vs 51.8 | 65 vs 65 vs 65 | Intravenous TXA + DEP vs intravenous TXA + topical DEP vs intravenous TXA | IV DEP (1 mg), IV TXA (10 mg/kg), topical DEP (0.25 mg, 1:200000) | 1, 2, 3, 4, 5, 6 | Hb < 70 g/l | 2 weeks |
| Wang JW 2017 | China | 67 vs 69 | 45 vs 45 | Topical TXA + topical DEP vs topical TXA | TXA (3 g), DEP (0.25 mg, 1:200000) | 1, 2, 3, 4, 5, 6 | Hb < 80 g/l | 2 months |
| Zhang JK 2017 | China | 62.5 vs 63.1 | 21 vs 34 | Topical TXA + topical DEP vs topical TXA | TXA (3 g), DEP (0.25 mg, 1:200000) | 1, 2, 3, 4, 5, 6 | Hb < 80 g/l | 6 months |
| Zhang JZ 2017 | China | 59.8 vs 60.3 vs 58.6 | 52 vs 52 vs 52 | Topical 1 g TXA + topical low dose DEP vs topical 1 g TXA + topical high dose DEP vs topical TXA | TXA (1 g), DEP (0.125 mg, 0.25 mg, 1:200000) | 1, 2, 3, 4, 5 | Hb < 70 g/l | 3 months |